Selling the Alinamin OTC business to Blackstone (2020)

The price of buying scale and selling the flagship

The core of this sale was that it met two aims — repairing the finances and narrowing the business — in one transaction. Having grown to the world’s top ten through the Shire acquisition, Takeda carried heavy debt as the price, and looked to non-core divestments for the means to repay it. That what was sold was Alinamin, the signboard product since the founding era, mirrors the underside of scaling up: compressing, with acquisition-swollen debt, the very business the acquisitions had widened. The selection and concentration that Kunio Takeda began a quarter-century earlier reached a punctuation mark with the letting-go of the consumer-drug business.

What remains is the question of how far a strategy that buys rather than grows can run. Rather than originate a product like Alinamin, which took long years to take root among the public, Takeda made up its scale with businesses obtained from outside — and let go of the consumer-drug earner. A structure concentrated on prescription drugs is also a wager on whether it can originate its next mainstay in-house. Alinamin, parted from the parent in 2021, can be re-read as one example of what an acquisition line that raised scale and debt together gained, and what it gave up.